Chronic heart failure – modification of treatment paradigm

Chronic heart failure – modification of treatment paradigm

The relevance of chronic heart failure (CHF) remains high. Despite significant advances in basic therapy for CHF patients, the prognosis remains poor. The prescription of inhibitors of sodium-glucose cotransporter type 2 dapagliflozin made it possible to change the paradigm of treatment of patients...

Full description

Bibliographic Details
Main Authors:	Svetlana N. Nasonova, Igor V. Zhirov, Sergey N. Tereshchenko
Format:	Article
Language:	Russian
Published:	ZAO "Consilium Medicum" 2022-01-01
Series:	Consilium Medicum
Subjects:	chronic heart failure dapagliflozin inhibitors of sodium-glucose cotransporter type 2
Online Access:	https://consilium.orscience.ru/2075-1753/article/viewFile/106338/80786

Similar Items

Safety of dapagliflozin initiation in acute decompensated heart failure patients with reduced left ventricular ejection fraction
by: Anastasiya E. Poskakalova, et al.
Published: (2023-07-01)

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure
by: Andrew Xanthopoulos, et al.
Published: (2023-08-01)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
by: Luis Ortega‐Paz, et al.
Published: (2023-02-01)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01)

Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
by: Anna Camps-Vilaró, et al.
Published: (2020-07-01)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
by: Benedetta Maria Bonora, et al.
Published: (2019-08-01)

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction
by: Oscar Eduardo Ospina González, et al.
Published: (2023-01-01)

Nephroprotective effect of dapagliflozin in type 2 diabetes mellitus: A potential role of Klotho protein
by: I. Topchii, et al.
Published: (2021-06-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients
by: Hidekatsu Yanai, et al.
Published: (2023-06-01)

Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial
by: Atsushi Tanaka, et al.
Published: (2022-12-01)

Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
by: Xiaolan Ouyang, et al.
Published: (2023-05-01)

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials
by: Yake Lou, et al.
Published: (2022-10-01)

Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
by: Dominik Kurczyński, et al.
Published: (2022-07-01)

Heart Failure: Prevention and Treatment are Indispensable
by: XU Fen, et al.
Published: (2022-11-01)

Diabetes Management in Patients with Heart Failure
by: Jia Shen, et al.
Published: (2021-03-01)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
by: Nikole J. Byrne, BSc, et al.
Published: (2017-08-01)

Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure
by: Milton Packer
Published: (2023-08-01)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
by: Mohammed Aldhaeefi, et al.
Published: (2023-03-01)

The use of quadrotherapy of chronic heart failure in cancer patients (case series)
by: Anton K. Peresada, et al.
Published: (2023-07-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia
by: Yu Horiuchi, et al.
Published: (2024-03-01)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
by: In-Chang Hwang, et al.
Published: (2020-05-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
by: Donato Cappetta, et al.
Published: (2021-12-01)

Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics
by: Vera N. Larina, et al.
Published: (2022-12-01)

Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study
by: Marcelino Cortés, et al.
Published: (2023-10-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
by: Ying Huang, et al.
Published: (2022-03-01)

Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial
by: Julie Hempel Larsen, et al.
Published: (2023-02-01)

Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis
by: Min Li, et al.
Published: (2022-07-01)

Heart Failure in Patients with Chronic Kidney Disease
by: Andrew Xanthopoulos, et al.
Published: (2023-09-01)

SGLT2 inhibitors in acute decompensated heart failure, what do we know?
by: Anastasiya E. Lapteva, et al.
Published: (2022-05-01)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
by: Juexing Li, et al.
Published: (2022-09-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022-11-01)

Acute decompensation of heart failure: state of the problem
by: Igor V. Zhirov, et al.
Published: (2022-10-01)

Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
by: Edoardo Gronda, et al.
Published: (2020-12-01)

Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure
by: Alex Ali Sayour, et al.
Published: (2021-07-01)

Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis
by: Diego Chambergo-Michilot, et al.
Published: (2021-02-01)

Management of Patients with Chronic Heart Failure and Diabetes Mellitus
by: E. V. Reznik, et al.
Published: (2021-05-01)

Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience
by: Erika Tabella, et al.
Published: (2023-08-01)